Therefore, combining PARP inhibitors with other drugs that inhibit the polarization of M2-type macrophages may enhance tumor cells’ sensitivity and immune response to PARP inhibitors (Ding et al., 2023). This evidence concerns the gene PARP1 and neoplasm.